MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13

YAVNE, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD ), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced an oral presentation at the Advanced Wound Care Summit taking place on July 13-14, 2022 in Boston, MA. The presentation, entitled: "Market Landscape Analysis & EscharEx Market Potential ," will be presented by Dr. Robert Snyder, Director of EscharEx Program at MediWound at 3:00 pm ET on Wednesday, July 13, 2022. Dr. Snyder will present an analysis of the wound care market and the potential for EscharEx use based on the recent study data. Interested parties may access a live and archived webcast of the presentation on the Events and Presentations section the Company's website. About the Advanced Wound Care Summit The Advanced Wound Care Summit is the first industry-led forum focused on delivering innovative wound care treatments to patients. Attendees will hear from, and discuss with, world leaders of wound care research who are driving the development of novel biomaterials, remote-monitoring devices, and digital health management solutions. About EscharEx EscharEx is a bioactive therapy for debridement of chronic and other hard-to-heal wounds in advanced stages of clinical development. Designed for the outpatient setting, EscharEx is an easy-to-use concentrate of proteolytic enzymes enriched in bromelain for topical daily applications. EscharEx was well-tolerated and demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds with only few daily applications in several Phase 2 trials. EscharEx's mechanism of action is mediated by the proteolytic enzymes that cleave and remove the necrotic tissue and prepare the wound bed for healing. About MediWound Ltd. MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn care, wound care and tissue repair. NexoBrid® , our commercial orphan biological product for non-surgical eschar removal of deep-partial and full-thickness ... Full story available on Benzinga.com